2,240 Shares in Amgen Inc. $AMGN Purchased by United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the second quarter, Holdings Channel reports. The firm acquired 2,240 shares of the medical research company’s stock, valued at approximately $811,000.

Other large investors also recently added to or reduced their stakes in the company. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC raised its stake in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Tower View Wealth Management LLC boosted its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the period. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new position in Amgen in the fourth quarter worth approximately $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 1.0%

Shares of NASDAQ AMGN opened at $419.38 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market capitalization of $226.73 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. The stock’s fifty day simple moving average is $372.05 and its two-hundred day simple moving average is $359.47. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $421.79.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts expect that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last quarter. 0.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their price target on Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Truist Financial lifted their price objective on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Wells Fargo & Company upped their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley increased their target price on shares of Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $372.39.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.